Nutriband (DE:9WV)
NASDAQ:9WV
9WV Stock Chart & Stats
€6.40
-€0.36(-7.96%)
At close: 4:00 PM EST
€6.40
-€0.36(-7.96%)
Day’s Range― - ―
52-Week Range€2.62 - €8.95
Previous CloseN/A
Volume0.00
Average Volume (3M)33.00
Market Cap
€37.19M
Enterprise Value€38.06M
Total Cash (Recent Filing)€4.57M
Total Debt (Recent Filing)€209.63K
Price to Earnings (P/E)―
Beta1.13
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding12,155,983
10 Day Avg. Volume0
30 Day Avg. Volume33
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)8.35
Price to Sales (P/S)27.38
P/FCF Ratio-10.86
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€13.01Price Target Upside103.34% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Market GrowthThe additional safety from the abuse-deterrent technology could potentially grow the market and drive upward revisions to estimates.
PartnershipsNutriband has a partnership with Kindeva Drug Delivery, formerly part of 3M, to add the AVERSA technology to Kindeva’s transdermal fentanyl patch.
Product DevelopmentThe AVERSA Fentanyl patch could prevent abuse and accidental misuse of fentanyl transdermal patches.
Bears Say
Development CostsNutriband and its partner, Kindeva, have amended their development and commercialization agreement covering AVERSA Fentanyl, the abuse-deterrent transdermal fentanyl patch in development.
Nutriband News
9WV FAQ
What was Nutriband’s price range in the past 12 months?
Nutriband lowest stock price was €2.62 and its highest was €8.95 in the past 12 months.
What is Nutriband’s market cap?
Nutriband’s market cap is €37.19M.
When is Nutriband’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Nutriband’s earnings last quarter?
Currently, no data Available
Is Nutriband overvalued?
According to Wall Street analysts Nutriband’s price is currently Undervalued.
Does Nutriband pay dividends?
Nutriband does not currently pay dividends.
What is Nutriband’s EPS estimate?
Nutriband’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nutriband have?
Nutriband has 12,155,983 shares outstanding.
What happened to Nutriband’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Nutriband?
Currently, no hedge funds are holding shares in DE:9WV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nutriband Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-39.36%
12-Months-Change
Fundamentals
Return on Equity
-118.30%
Trailing 12-Months
Asset Growth
1.04%
Trailing 12-Months
Company Description
Nutriband
Nutriband Inc. specializes in developing a diverse range of pharmaceutical products delivered via transdermal patches. The company's most advanced program centers on AVERSA fentanyl, an innovative fentanyl transdermal system engineered to prevent abuse. This extended-release patch provides healthcare professionals and patients with a continuous opioid therapy solution for the ongoing management of chronic pain. Its development pipeline also includes other treatments, such as AVERSA buprenorphine and AVERSA methylphenidate. Additionally, Nutriband is working on exenatide for individuals with type 2 diabetes and follicle stimulating hormone as a treatment for infertility. The company also holds a licensing agreement with Rambam Med-Tech Ltd. to further the development of RAMBAM Closed System Transfer Devices. Nutriband Inc. was founded in 2016 and its main offices are located in Orlando, Florida.
9WV Stock 12 Month Forecast
Average Price Target
€13.01
▲(103.34% Upside)
Technical Analysis
Champions Oncology
―
InflaRx
―
Pliant Therapeutics
―
ALX Oncology Holdings
―
Adagene
―
Options Prices
Currently, No data available
---